MA44547A1 - Anticorps anti-pd-1,procédé de leur production et de leur utilisation - Google Patents

Anticorps anti-pd-1,procédé de leur production et de leur utilisation

Info

Publication number
MA44547A1
MA44547A1 MA44547A MA44547A MA44547A1 MA 44547 A1 MA44547 A1 MA 44547A1 MA 44547 A MA44547 A MA 44547A MA 44547 A MA44547 A MA 44547A MA 44547 A1 MA44547 A1 MA 44547A1
Authority
MA
Morocco
Prior art keywords
antibodies
human
relates
oncology
present
Prior art date
Application number
MA44547A
Other languages
English (en)
Other versions
MA44547B1 (fr
Inventor
Olga Vladimirovna Goncharova
Andrei Borisovich Ulitin
Roman Alekseevich Ivanov
Korzhavin Dmitry Valeryevich -
Yulia Sergeevna Chernykh
Timofey Aleksandrovich -Nemankin
Valery Vladimirovich Solovyev
Anna Konstantinovna Vladimirova
Irina Andreevna Bulankina
Sergei Vasilyevich Diduk
Anna Vladimirovna Eroshova
Iakov Iurevich Ustiugov
Marina Vladimirovna Artiukhova
Dmitry Valentinovich Morozov
Original Assignee
Biocad Joint Stock Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocad Joint Stock Co filed Critical Biocad Joint Stock Co
Publication of MA44547A1 publication Critical patent/MA44547A1/fr
Publication of MA44547B1 publication Critical patent/MA44547B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne la biotechnologie et se présente comme des anticorps monoclonaux extraits, notamment des anticorps monoclonaux humains qui se lient spécifiquement à pd-1 avec une affinité élevée. Les anticorps de l’invention peuvent être chimériques, humanisés ou humains ou leurs fragments de liaison d’antigènes et peuvent s'utiliser en tant que médicament en oncologie ou oncologie immunitaire pour la thérapie des maladies liées à diverses perturbations de la prolifération et de développement des cellules. L'invention concerne aussi des procédés de production de ces anticorps et une méthode de traitement des maladies humaines au moyen des anticorps présents.
MA44547A 2016-07-13 2017-07-04 Anticorps anti-pd-1,procédé de leur production et de leur utilisation MA44547B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2016128487A RU2656181C1 (ru) 2016-07-13 2016-07-13 Анти-pd-1-антитела, способ их получения и способ применения
PCT/RU2017/050056 WO2018013017A1 (fr) 2016-07-13 2017-07-04 Anticorps anti-pd-1, procédé de leur production et de leur utilisation

Publications (2)

Publication Number Publication Date
MA44547A1 true MA44547A1 (fr) 2020-01-31
MA44547B1 MA44547B1 (fr) 2021-09-30

Family

ID=60953256

Family Applications (1)

Application Number Title Priority Date Filing Date
MA44547A MA44547B1 (fr) 2016-07-13 2017-07-04 Anticorps anti-pd-1,procédé de leur production et de leur utilisation

Country Status (21)

Country Link
US (1) US11136408B2 (fr)
EP (1) EP3486257A4 (fr)
JP (1) JP6993992B2 (fr)
KR (1) KR102482710B1 (fr)
CN (1) CN110023335B (fr)
BR (1) BR112019000436A2 (fr)
CA (1) CA3021372A1 (fr)
CL (1) CL2018003407A1 (fr)
CO (1) CO2019001246A2 (fr)
CR (1) CR20190009A (fr)
EC (1) ECSP19010852A (fr)
JO (1) JOP20190002A1 (fr)
MA (1) MA44547B1 (fr)
MX (1) MX2018014937A (fr)
NI (1) NI201900002A (fr)
NZ (1) NZ750221A (fr)
PE (1) PE20190450A1 (fr)
PH (1) PH12018550179A1 (fr)
RU (1) RU2656181C1 (fr)
WO (1) WO2018013017A1 (fr)
ZA (1) ZA201900792B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201804178YA (en) 2015-11-18 2018-06-28 Merck Sharp & Dohme Pd1 and/or lag3 binders
WO2018133842A1 (fr) 2017-01-20 2018-07-26 大有华夏生物医药集团有限公司 Anticorps monoclonal du récepteur de mort programmée humain pd-1 et fragment de celui-ci
CA3058966A1 (fr) 2017-04-14 2018-10-18 Tollnine, Inc. Polynucleotides immunomodulateurs, conjugues d'anticorps de ceux-ci, et procedes d'utilisation associes
AU2018282094B2 (en) 2017-06-05 2024-06-27 Janssen Biotech, Inc. Antibodies that specifically bind PD-1 and methods of use
ES2910969T3 (es) 2017-08-03 2022-05-17 Amgen Inc Muteínas de interleucina-21 y métodos de tratamiento
TW201930344A (zh) 2018-01-12 2019-08-01 美商安進公司 抗ｐｄ-１抗體及治療方法
WO2019148410A1 (fr) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anticorps anti-pd-1
EP3823991A4 (fr) * 2018-07-19 2022-08-03 Tayu Huaxia Biotech Medical Group Co., Ltd. Anticorps anti-pd-1, dosages et utilisations de ceux-ci
CN109652453B (zh) * 2018-12-29 2021-04-06 杭州科兴生物科技有限公司 一种基于pd-1/pdl-1阻断功能及生物效应的抗癌药物快速筛选方法
CN113874036A (zh) 2019-05-24 2021-12-31 辉瑞公司 使用cdk抑制剂的联合治疗
AU2020290971A1 (en) * 2019-06-14 2021-12-23 Dana-Farber Cancer Institute, Inc. Antibodies against PD-1 and methods of use thereof
CN111420049A (zh) * 2019-08-22 2020-07-17 Biocad股份公司 抗-pd1抗体prolgolimab的水性药物组合物及其应用
RU2753282C2 (ru) * 2019-09-19 2021-08-12 Закрытое Акционерное Общество "Биокад" ИММУНОЦИТОКИН, ВКЛЮЧАЮЩИЙ ГЕТЕРОДИМЕРНЫЙ БЕЛКОВЫЙ КОМПЛЕКС НА ОСНОВЕ IL-15/IL-15Rα, И ЕГО ПРИМЕНЕНИЕ
IL295759A (en) 2020-02-28 2022-10-01 Tallac Therapeutics Inc Transglutaminase mediated coupling
PH12022553181A1 (en) 2020-05-26 2024-03-04 Boehringer Ingelheim Int Anti-pd-1 antibodies
US20220168293A1 (en) 2020-12-02 2022-06-02 Pfizer Inc. Time to resolution of axitinib-related adverse events
EP4261225A4 (fr) * 2020-12-10 2024-11-13 Eutilex Co., Ltd. Anticorps anti-pd-1 et ses utilisations
PE20241732A1 (es) 2021-03-31 2024-08-19 Merus Nv Dominios de union a pd-1 novedosos
UY39724A (es) 2021-04-08 2022-10-31 Biocad Joint Stock Co Método para tratar una neoplasia maligna mediante la combinación de un anticuerpo contra pd-1 y un a
TW202327595A (zh) 2021-10-05 2023-07-16 美商輝瑞大藥廠 用於治療癌症之氮雜內醯胺化合物的組合
WO2023079428A1 (fr) 2021-11-03 2023-05-11 Pfizer Inc. Polythérapies utilisant un agoniste de tlr7/8
CN120225558A (zh) * 2022-10-05 2025-06-27 朱拉隆功大学 针对人程序性细胞死亡蛋白1(pd-1)的单克隆抗体

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2720160T3 (es) * 2005-05-09 2019-07-18 Ono Pharmaceutical Co Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas
JP5191537B2 (ja) * 2007-06-18 2013-05-08 エム・エス・ディー・オス・ベー・フェー ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体
US8062852B2 (en) * 2007-10-01 2011-11-22 The Children's Hospital And Regional Medical Center Detection and treatment of autoimmune disorders
PT2504364T (pt) * 2009-11-24 2017-11-14 Medimmune Ltd Agentes de ligação direcionados contra b7-h1
CA2791930A1 (fr) * 2010-03-11 2011-09-15 Kerry Louise Tyson Anticorps pd-1
TW201134488A (en) * 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
BR112013024574B1 (pt) * 2011-03-29 2022-08-09 Roche Glycart Ag Anticorpo e uso do anticorpo
KR102243062B1 (ko) * 2013-05-02 2021-04-21 아납티스바이오, 아이엔씨. 예정된 사멸-1에 대한 항체
JP6623353B2 (ja) * 2013-09-13 2019-12-25 ベイジーン スウィッツァーランド ゲーエムベーハー 抗ｐｄ−１抗体並びにその治療及び診断のための使用
HRP20201153T1 (hr) * 2014-08-08 2021-01-22 The Board Of Trustees Of The Leland Stanford Junior University Pd-1 sredstva visokog afiniteta i načini uporabe
GB201419084D0 (en) * 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-PD-1 antibodies
TWI595006B (zh) * 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法

Also Published As

Publication number Publication date
EP3486257A1 (fr) 2019-05-22
CN110023335B (zh) 2024-05-17
US20190127478A1 (en) 2019-05-02
AU2017297138A8 (en) 2019-02-28
NZ750221A (en) 2022-09-30
EP3486257A4 (fr) 2020-03-04
CA3021372A1 (fr) 2018-01-18
WO2018013017A1 (fr) 2018-01-18
US11136408B2 (en) 2021-10-05
BR112019000436A2 (pt) 2019-10-01
MX2018014937A (es) 2019-05-16
CL2018003407A1 (es) 2019-03-29
JOP20190002A1 (ar) 2019-01-10
KR102482710B1 (ko) 2023-01-02
ZA201900792B (en) 2020-03-25
CN110023335A (zh) 2019-07-16
PE20190450A1 (es) 2019-03-29
AU2017297138A2 (en) 2019-02-21
NI201900002A (es) 2019-06-11
AU2017297138A1 (en) 2019-02-14
CR20190009A (es) 2019-06-05
ECSP19010852A (es) 2019-06-30
CO2019001246A2 (es) 2019-02-19
MA44547B1 (fr) 2021-09-30
PH12018550179A1 (en) 2019-03-11
JP2019527543A (ja) 2019-10-03
RU2656181C1 (ru) 2018-05-31
JP6993992B2 (ja) 2022-01-14
KR20190029641A (ko) 2019-03-20

Similar Documents

Publication Publication Date Title
MA44547A1 (fr) Anticorps anti-pd-1,procédé de leur production et de leur utilisation
MA49599B1 (fr) Anticorps spécifiques à cd47 et pd-l1
PH12022552122A1 (en) Antibodies and fusion proteins that bind to ccr8 and uses thereof
EA201990781A9 (ru) Анти-steap2 антитела, конъюгаты антитело-лекарственное средство и биспецифические антигенсвязывающие молекулы, которые связывают steap2 и cd3, и их применение
EA201990171A1 (ru) Биспецифичное антитело против egfr и против cd3 и его применения
MY207784A (en) Anti-cd73 antibodies
PH12018501220A1 (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
MA42622B1 (fr) Agents de liaison à tigit et leurs utilisations
SG10201908259WA (en) Methods of reducing serum levels of fc-containing agents using fcrn antagonsits
MX2022007035A (es) Polipeptidos que comprenden dominios variables unicos de inmunoglobulina que se dirigen a il-13 y tslp.
EA201992755A1 (ru) Новые моноклональные антитела к белку 4, ассоциированному с цитотоксическими т-лимфоцитами, (ctla-4)
MA40913A (fr) Conjugués anticorps-médicament
MA42542B1 (fr) Molécules se liant à pd-1 et méthodes d'utilisation correspondantes
MA37761A1 (fr) Protéines de liaison à un antigène antagoniste d'un double récepteur et leurs utilisations
EA202091569A1 (ru) Моноклональные антитела и способы их применения
MA47221A1 (fr) Anticorps monoclonal à pd-l1
MX2023004869A (es) Anticuerpos contra sars-cov-2 y usos de los mismos.
MY205967A (en) Monoclonal antibodies against the beta chain region of human trbv9
MY206214A (en) Monoclonal antibodies that bind specifically to human trbv9
EA202092125A1 (ru) Антитела против рецептора фолата 1 и их применения
MX2022008421A (es) Anticuerpo anti-galectina-9 y usos del mismo.
MX2020009743A (es) Anticuerpos monoclonales neutralizantes de alta afinidad dirigidos contra el ligando de muerte programada 1 (pd-l1) y usos de estos.
MA49607B2 (fr) ANTICORPS MONOCLONAL POUR IL-5Rα
TH1901000154A (th) แอนติบอดีต้าน pd-1, วิธีการผลิตและวิธีการใช้ของสิ่งดังกล่าว
EA202091738A1 (ru) Способы лечения рака антителами-антагонистами к pd-1